AstraZeneca has forged a wide-ranging collaboration with Chinese biotech CSPC Pharma that will focus on the use of artificial intelligence (AI) to find new medicines across a range of diseases.

Stay up to date with key industry meetings and conferences in 2024 In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.

In recent years, pharma companies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time between ...

Since the onset of the Covid-19 pandemic, life science companies have acted quickly to address the evolving digital needs of healthcare professionals, with mixed success (see graph 1). In the age ...

Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies. The article ...

A new policy from the NIH in the US will cut billions of dollars of funding for research organisations and hospitals outside the US, in another signal of America's retreat from the world stage.

The healthcare systems of the future will be very different to those of today, with prevention and self-management increasingly important. Pharma must adapt its approach and collaborate with a ...

CVS Health and Walgreens have become the first two US pharmacy chains to agree a settlement worth nearly $10 billion to answer allegations they played a role in the opioid epidemic that has ...

Across the world, there are reports of shortages of common antibiotics. Ben Hargreaves examines why these shortages are happening and what is being done in the background to return supply to ...

The recent launch of SearchGPT by OpenAI marks the beginning of a significant shift in how information is searched and consumed for pharma and healthcare industry leaders. Unlike traditional ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

The Biophysics for Drug Discovery Summit is the definitive, industry-dedicated forum bringing you the latest advancements, discoveries, applications and transferrable lessons of utilizing ...